Approval · Notice of Compliance 35928 · 2025
ELAHERE: Notice of Compliance 35928
Issued August 29, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35928
- Date
- August 29, 2025
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ELAHERE | 02560771 | Marketed |
Medicinal ingredients
- MIRVETUXIMAB SORAVTANSINE 100 MG per 20ML